
PF-04971729
CAS No. 1210344-57-2
PF-04971729( Ertugliflozin | MK-8835 | PF-4971729 )
Catalog No. M10784 CAS No. 1210344-57-2
A potent and selective SGLT2 inhibitor with IC50 of 0.877 nM for hSGLT2.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 41 | In Stock |
![]() ![]() |
10MG | 57 | In Stock |
![]() ![]() |
50MG | 87 | In Stock |
![]() ![]() |
100MG | 133 | In Stock |
![]() ![]() |
200MG | 214 | In Stock |
![]() ![]() |
500MG | 353 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePF-04971729
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective SGLT2 inhibitor with IC50 of 0.877 nM for hSGLT2.
-
DescriptionA potent and selective SGLT2 inhibitor with IC50 of 0.877 nM for hSGLT2; shows >2000-fold selectivity over hSGLT1; demonstrates robust urinary glucose excretion in rats and an excellent preclinical safety profile.Diabetes Phase 3 Clinical(In Vitro):Ertugliflozin (PF-04971729) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro.(In Vivo):Ertugliflozin (PF-04971729) reveals a concentration-dependent glucosuria after oral administration to rats.
-
In Vitro——
-
In Vivo——
-
SynonymsErtugliflozin | MK-8835 | PF-4971729
-
PathwayGPCR/G Protein
-
TargetSGLT
-
RecptorSGLT2
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number1210344-57-2
-
Formula Weight436.8827
-
Molecular FormulaC22H25ClO7
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 46 mg/mL
-
SMILESO[C@@H]1[C@](O2)(CO)CO[C@]2(C3=CC=C(Cl)C(CC4=CC=C(C=C4)OCC)=C3)[C@H](O)[C@H]1O
-
Chemical Nameβ-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mascitti V, et al. J Med Chem. 2011 Apr 28;54(8):2952-60.
2. Kalgutkar AS, et al. Drug Metab Dispos. 2011 Sep;39(9):1609-19.
3. Miao Z, et al. Drug Metab Dispos. 2013 Feb;41(2):445-56.
molnova catalog



related products
-
KGA-2727
KGA-2727 is a potent and selective SGLT1 inhibitor, with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively.?The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat).?KGA-2727 for the treatment of diabete.KGA-2727, which has a pyrazole-O-glucoside structure, as the first selective SGLT1 inhibitor.?
-
Canagliflozin
A highly potent and selective SGLT2 inhibitor with IC50 of 4.4, 3.7 and 2.0 nM for hSGLT2, rSGLT2 and mSGLT2, respectively.
-
Licogliflozin
A novel sodium glucose transporter type 1 and type 2 (SGLT1/2) inhibitor for the oral treatment of type 2 diabetes.